中华医学杂志（英文版）2011，Vol.124Issue(7)：1055-1060,6.DOI:10.3760/cma.j.issn.0366-6999.2011.07.020
Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
摘要
Abstract
Background Mounting evidence suggests that tumors are histologically heterogeneous and are maintained by a small population of tumor cells termed cancer stem cells. CD133 has been identified as a candidate marker of cancer stem cells in laryngeal carcinoma. This study aimed to analyze the chemoresistance of CD133+ cancer stem cells.Methods The response of Hep-2 cells to different chemotherapeutic agents was investigated and the expression of CD133 was studied. Fluorescence-activated cell sorting analysis was used to identify CD133,and the CD133+ subset of cells was separated and analyzed in colony formation assays,cell invasion assays,chemotherapy resistance studies,and analyzed for the expression of the drug resistance gene ABCG2.Results About 1%-2% of Hep-2 cells were CD133+ cells,and the CD133+ proportion was enriched by chemotherapy.CD133+ cancer stem cells exhibited higher potential for clonogenicity and invasion,and were more resistant to chemotherapy. This resistance was correlated with higher expression of ABCG2.Conclusions This study suggested that CD133+ cancer stem cells are more resistant to chemotherapy. The expression of ABCG2 could be partially responsible for this. Targeting this small population of CD133+ cancer stem cells could be a strategy to develop more effective treatments for laryngeal carcinoma.关键词
CD133/cancer stem cells/Hep-2 cells/laryngeal carcinomaKey words
CD133/cancer stem cells/Hep-2 cells/laryngeal carcinoma引用本文复制引用
YANG Jing-pu,LIU Yan,ZHONG Wei,YU Dan,WEN Lian-ji,JIN Chun-shun..Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma[J].中华医学杂志（英文版）,2011,124(7):1055-1060,6.基金项目
This research was supported by a grant from the National Natural Science Foundation of China (No.30973288). （No.30973288）
